Indications :
For Mantle Cell Lymphoma (MCL) patients who have undergone at least one prior therapy.Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) treatment.Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with 17p deletion.Waldenstrom Macroglobulinemia (WM) management.Marginal Zone Lymphoma (MZL) treatment for patients requiring systemic therapy after previous anti-CD 20-based treatment.

Pharmacology:
Ibrutix 140 mg functions as a small-molecule inhibitor of BTK (Bruton’s tyrosine kinase). It forms a covalent bond with a cysteine residue in the BTK active site, leading to the inhibition of BTK enzymatic activity. BTK plays a crucial role in signaling through the B-cell antigen receptor (BCR) and cytokine receptor pathways, influencing pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies demonstrate that Ibrutix 140 mg inhibits malignant B-cell proliferation and survival in vivo, along with cell migration and substrate adhesion in vitro.

Dosage and Administration:
For Mantle Cell Lymphoma and Marginal Zone Lymphoma: The recommended dose is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia (WM): The recommended dose is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity. Additionally, when used in combination with bendamustine and rituximab, the recommended dose remains 420 mg (three 140 mg capsules) orally once daily for up to 6 cycles.Administer orally once daily at approximately the same time each day. Swallow the capsules whole with water; do not open, break, or chew them.

Interaction :
Avoid co-administration with strong and moderate CYP3A inhibitors. If necessary, reduce Ibrutix 140 mg dose when used with moderate CYP3A inhibitors. Co-administration with strong CYP3A inducers should be avoided.

Side Effects :
Common adverse reactions include hemorrhage, infections, cytopenias, atrial fibrillation, hypertension, second primary malignancies, tumor lysis syndrome, diarrhea, and visual disturbance.

Precautions and Warnings:
Hypersensitivity to the active substance or excipients serves as a contraindication.

Overdose Effects :
Specific overdose management experiences are lacking. Monitor closely and provide appropriate supportive treatment in case of overdose.